Association between the composite CRP–TyG index and incident malignancy risk in hospitalized patients with diabetes: a retrospective cohort study with nonlinear effect analysis - Takeaways - MDSpire

Association between the composite CRP–TyG index and incident malignancy risk in hospitalized patients with diabetes: a retrospective cohort study with nonlinear effect analysis

  • By

  • Xinyuan Cui

  • Mengru Yuan

  • Yanting Mao

  • Bojin Xu

  • Haiping Zhou

  • Shan Huang

  • Wenfang Peng

  • May 18, 2026

Share

  • 1

    The CRP–TyG composite index is a significant marker for assessing cancer risk in hospitalized patients with diabetes.

  • 2

    A total of 5,500 diabetic inpatients were analyzed, revealing 344 incident malignancies during the study period.

  • 3

    Malignancy risk increased progressively across CRP–TyG quartiles, with the highest quartile showing a 92% increased risk.

  • 4

    A nonlinear association was identified, with a notable inflection point at a CRP–TyG z-score of 0.62.

  • 5

    The composite index outperformed CRP or TyG alone in predicting gastrointestinal cancer risk among diabetic patients.

Original Source(s)

Association between the composite CRP–TyG index and incident malignancy risk in hospitalized patients with diabetes: a retrospective cohort study with nonlinear effect analysis

  • by Xinyuan Cui, Mengru Yuan, Yanting Mao, Bojin Xu, Haiping Zhou, Shan Huang, Wenfang Peng

  • May 18, 2026

Related Content

Neoadjuvant Single-Cycle Pembrolizumab for Stage I to III dMMR Colon Cancer

In a Danish phase II trial (RESET-C) reported in the Journal of Clinical Oncology, Gögenur et al found that a single cycle of neoadjuvant pembrolizumab was associated with pathologic complete response...

Study Finds Prostate Cancer Overdiagnosis Rises ‘Substantially’ With Age

Investigators have found that overdiagnosis of prostate cancer through prostate-specific antigen screening is low in younger men—but rises sharply with age.

FDA Approves Fam-Trastuzumab Deruxtecan-nxki Indications in HER2-Positive Early Breast Cancer

On May 15, 2026, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu) for two separate indications for the treatment of adult patients with HER2-positive earl...